Axid AR cleared by FDA on May 9; Whitehall touting 30-minute onset of action.
This article was originally published in The Tan Sheet
Executive Summary
WHITEHALL-ROBINS' AXID AR 30-MINUTE ONSET OF ACTION in preventing heartburn is being emphasized by the company in press materials announcing FDA approval of the Rx-to-OTC switch product. The agency cleared the application for nizatidine 75 mg on May 9. The fourth OTC H2 antagonist to receive FDA switch clearance, Axid AR is indicated for the prevention of heartburn, acid indigestion and sour stomach.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
People In Brief
Perrigo promotes in pricing, planning
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: